SLC6A3 and supranuclear palsy, progressive, 1: Given that severely decreased DAT bindings were found in both PSP-RS and PSP-non-RS subtypes (Chen et al., 2022) and the contribution of the dopaminergic lesions to the disease severity in PSP has never been explored before, we conducted this cross-sectional study aiming to explore the contribution of dopaminergic lesions to the disease severity in PSP, with the DAT positron emission tomography (PET) imaging in a relatively large PSP cohort with various subtypes.